Interim reports of DR-TB Treatment

Content Status

Published on LMS

Type

Linked Node

Interim reports of DR-TB Treatment

Learning Objectives

Explain the interim report, and why it is important. Criteria to be fulfilled, how to interpret, and what does it mean? Explain the decisive importance of the interim reports.

Content

As Drug-resistant TB (DR-TB) treatment is of relatively long duration, the interim treatment reports are prepared in Ni-kshay to assess the interim treatment outcomes in the programme.

Criteria

The interim report assessment period is six calendar months, usually counted from January to the end of June and July to the end of December.
All patients registered and starting treatment during the assessment period are included in the calculation.

Interpretation

Interim results of DR-TB patients who started treatment during the first semester of a year (1 January to 30 June), should be calculated at the beginning of April of the following year.
The interim report form should be completed 9 months after the closing day of the cohort so as to allow culture information at 6 months of treatment to be included for all patients in the cohort.

Sl. No.	DR-TB Regimen	Time point for interim reporting	Cohort for interim evaluation, reporting and monitoring (Here ‘X’ is the reporting month)	If reporting month is X= April 2023, following are the corresponding cohort for interim report evaluation
1	Isoniazid (H) - mono/ poly DR-TB regimen	4th month of treatment	X - 6 months	Cohort of October 2022 and previous
2	Shorter oral Bedaquiline-containing Multidrug-resistant (MDR)/ Rifampicin-resistant (RR)-TB regimen	4th month of treatment	X - 6 months	Cohort of October 2022 and previous
3	Longer oral Multidrug-resistant/ Extensively Drug-resistant TB (M/XDR-TB) regimen	6th month of treatment	X - 10 months	Cohort of June 2022 and previous
4	BPal (Bedaquiline, Pretomanid, Linezolid) regimen	4th month of treatment	X - 6 months	Cohort of October 2022 and previous
5	Prior longer M/XDR-TB regimen (Drug Susceptibility Testing (DST) guided regimen)	6th month of treatment	X - 10 months	Cohort of June 2022 and previous

Importance

Culture conversion (for confirmed DR-TB cases) and death by six months are important predictors of final outcomes.
It also provides early information on the number of patients initiated on second-line drugs for MDR-TB that turned out not to be XDR.
Information on treatment interruption at the end of six months is important for programme review and implementing corrective actions.
Overall interim reports are important for supervision, monitoring and evaluation at all programmatic levels.

Resources

Guidelines on Programmatic Management of Drug-resistant TB (PMDT) in India, 2021, CTD, MoHFW, India.

Assessment

Question	Answer 1	Answer 2	Answer 3	Answer 4	Correct answer	Correct explanation	Page id	Part of Pre-test	Part of Post-test
What is the duration of the assessment of the interim report in NTEP?	2 Calendar months	3 Calendar months	6 Calendar months	12 Calendar months	3	The interim report assessment period is six calendar months, usually counted from January to the end of June and July to the end of December.		Yes	Yes